Two Distinct Clinical Patterns of Ibrutinib‐to‐Venetoclax Transition in Relapsed Chronic Lymphocytic Leukemia Patients

Abstract

Patients with chronic lymphocytic leukemia (CLL) relapsing on ibrutinib are often treated with the Bcl‐2 inhibitor venetoclax. However, the transition from one agent to another poses some clinical challenges due to disease flares sometimes occurring right after ibrutinib interruption. Here, we describe three clinical vignettes highlighting two distinct patterns of ibrutinib‐to‐venetoclax transition. While patients following the favorable pattern transited to venetoclax without experienc-ing disease flare, the one patient who took the unfavorable path showed rapid disease rebound, with large‐cell transformation occurring one week after ibrutinib interruption. A high burden of BTK and PLCG2 mutations was found only in patients with the favorable transition pattern, sug-gesting that removing BTK inhibition might be particularly harmful if CLL cells are progressing through mechanisms external to the BTK axis.